Myoclonus-Dystonia Syndrome

Genetic MONDO:0000903 Pathograph 23 dystonic disorder movement disorder autosomal dominant disease

Myoclonus-dystonia syndrome is a rare, usually childhood-onset movement disorder characterized by brief myoclonic jerks with dystonia, prominent upper body involvement, alcohol responsiveness, and frequent psychiatric features. Pathogenic variants in SGCE, and less commonly KCTD17, disrupt movement-circuit function; SGCE-related disease shows autosomal dominant inheritance with maternal imprinting and reduced penetrance after maternal transmission.

Ask OpenScientist

Ask a research question about Myoclonus-Dystonia Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
12
Phenotypes
23
Pathograph
2
Genes
6
Treatments
1
Subtypes
10
References
1
Deep Research
👪

Inheritance

1
Autosomal dominant inheritance with maternal imprinting HP:0000006
SGCE-related myoclonus-dystonia is autosomal dominant, but penetrance depends on parental origin because maternally inherited SGCE alleles are usually silenced.
Autosomal dominant inheritance
Show evidence (2 references)
ORPHA:36899 SUPPORT Other
"- Autosomal dominant"
Orphanet lists autosomal dominant inheritance.
PMID:20301587 SUPPORT Human Clinical
"SGCE-M-D is inherited in an autosomal dominant manner with penetrance determined by the parental origin of the altered SGCE allele: an SGCE pathogenic variant on the paternally derived (expressed) SGCE allele generally results in disease; a pathogenic variant on the maternally derived (silenced)..."
GeneReviews describes autosomal dominant inheritance with imprinting-dependent penetrance.
◆

Subtypes

1
Myoclonic dystonia 11 MONDO:0008044
SGCE-related myoclonus-dystonia is the major genetically defined form and is caused by pathogenic variants in SGCE.
Show evidence (1 reference)
PMID:11528394 SUPPORT Human Clinical
"Using a positional cloning approach, we have identified five different heterozygous loss-of-function mutations in the gene for epsilon-sarcoglycan (SGCE), which we mapped to a refined critical region of about 3.2 Mb."
This positional-cloning study establishes SGCE-related myoclonus-dystonia.
⚙

Pathophysiology

7
Epsilon-sarcoglycan trafficking and membrane loss
SGCE pathogenic variants reduce functional epsilon-sarcoglycan at the plasma membrane through intracellular retention, polyubiquitination, and proteasomal degradation of mutant protein.
SGCE link
protein localization to plasma membrane link ↓ DECREASED protein ubiquitination link ↑ INCREASED
Downstream
Altered cerebello-thalamic pathway function
Show evidence (2 references)
PMID:17200151 SUPPORT In Vitro
"In contrast to the wild-type protein, disease-associated epsilon-sarcoglycan missense mutations (H36P, H36R and L172R) produce proteins that are undetectable at the cell surface and are retained intracellularly."
Cultured-cell data directly support impaired plasma-membrane trafficking of mutant epsilon-sarcoglycan.
PMID:17200151 SUPPORT In Vitro
"These mutant proteins become polyubiquitinated and are rapidly degraded by the proteasome."
The same study supports ubiquitin-proteasome processing of mutant epsilon-sarcoglycan.
GABAergic/Purkinje cell dysfunction
Myoclonus-dystonia motor-network dysfunction may involve a GABAergic deficit reflecting Purkinje-cell dysfunction.
Purkinje cell link
synaptic transmission, GABAergic link ↓ DECREASED
Downstream
Altered cerebello-thalamic pathway function
Show evidence (1 reference)
PMID:29952836 SUPPORT Other
"Accumulating evidence suggests that an alteration in cerebello-thalamic pathway function may play a prominent role and that this is possibly related to a GABAergic deficit reflecting Purkinje cell dysfunction."
This review supports GABAergic/Purkinje-cell dysfunction as an intermediate mechanism.
Impaired striatal plasticity
Impaired striatal plasticity is implicated as a basal-ganglia circuit mechanism contributing to the myoclonus-dystonia motor phenotype.
regulation of synaptic plasticity link ↓ DECREASED
Downstream
Myoclonus
Limb myoclonus
Spinal myoclonus
Dystonia
Show evidence (1 reference)
PMID:29952836 SUPPORT Other
"Impaired striatal plasticity and disturbed serotonin homeostasis may also be implicated."
This review supports impaired striatal plasticity as a separate motor-circuit mechanism.
Disturbed serotonin homeostasis
Disturbed serotonin homeostasis is implicated as another neurotransmitter mechanism in the myoclonus-dystonia motor circuit.
Downstream
Myoclonus
Dystonia
Show evidence (1 reference)
PMID:29952836 SUPPORT Other
"Impaired striatal plasticity and disturbed serotonin homeostasis may also be implicated."
This review supports disturbed serotonin homeostasis as a distinct implicated mechanism.
Calcium homeostasis disturbance
Epsilon-sarcoglycan dysfunction may alter calcium homeostasis and dopaminergic membrane stabilization, contributing to abnormal cerebello-thalamo-pallido-cortical network development and function.
calcium ion homeostasis link ⚠ ABNORMAL
Downstream
Altered cerebello-thalamic pathway function
Show evidence (1 reference)
PMID:31449710 SUPPORT Other
"Finally, we critically discuss the normal and pathological function of the epsilon-sarcoglycan gene and its product, suggesting a role in the stabilization of the dopaminergic membrane via regulation of calcium homeostasis and in the neurodevelopmental process involving the..."
This mechanistic review supports calcium-homeostasis disturbance as a distinct epsilon-sarcoglycan mechanism.
Altered cerebello-thalamic pathway function
Altered cerebello-thalamic pathway function is the central motor-network event linking upstream SGCE mechanisms to myoclonus and dystonia.
Downstream
Myoclonus
Limb myoclonus
Spinal myoclonus
Dystonia
Cervical dystonia
Writer's cramp
Show evidence (2 references)
PMID:29952836 SUPPORT Other
"Accumulating evidence suggests that an alteration in cerebello-thalamic pathway function may play a prominent role and that this is possibly related to a GABAergic deficit reflecting Purkinje cell dysfunction."
This review supports altered cerebello-thalamic pathway function as a central mechanism.
PMID:31449710 SUPPORT Other
"Finally, we critically discuss the normal and pathological function of the epsilon-sarcoglycan gene and its product, suggesting a role in the stabilization of the dopaminergic membrane via regulation of calcium homeostasis and in the neurodevelopmental process involving the..."
This mechanistic review supports cerebello-thalamo-pallido-cortical network involvement.
SGCE-associated psychiatric vulnerability
SGCE pathogenic variants have pleiotropic neuropsychiatric effects that increase compulsivity, anxiety, alcohol dependence, and other psychiatric symptoms in addition to the motor phenotype.
SGCE link
Downstream
Compulsive behaviors
Anxiety
Depression
Panic attack
Show evidence (1 reference)
PMID:23365103 SUPPORT Human Clinical
"SGCE mutations are associated with a specific psychiatric phenotype consisting of compulsivity, anxiety and alcoholism in addition to the characteristic motor phenotype."
This SGCE mutation-positive cohort supports psychiatric vulnerability as part of the syndrome.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Myoclonus-Dystonia Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

12
Nervous System 5
Myoclonus VERY_FREQUENT Myoclonus (HP:0001336)
Show evidence (2 references)
ORPHA:36899 SUPPORT Other
"HP:0001336 | Myoclonus | Very frequent (99-80%)"
Orphanet lists myoclonus as very frequent.
PMID:20301587 SUPPORT Human Clinical
"The myoclonic jerks typical of SGCE-M-D most often affect the neck, trunk, and upper limbs with less common involvement of the legs."
GeneReviews describes the distribution of typical SGCE-related myoclonic jerks.
Dystonia VERY_FREQUENT Dystonia (HP:0001332)
Show evidence (2 references)
ORPHA:36899 SUPPORT Other
"HP:0001332 | Dystonia | Very frequent (99-80%)"
Orphanet lists dystonia as very frequent.
PMID:20301587 SUPPORT Human Clinical
"Approximately 50% of affected individuals have additional focal or segmental dystonia, presenting as cervical dystonia and/or writer's cramp."
GeneReviews supports focal or segmental dystonia as part of SGCE-related disease.
Compulsive behaviors FREQUENT Compulsive behaviors (HP:0000722)
Show evidence (2 references)
ORPHA:36899 SUPPORT Other
"HP:0000722 | Compulsive behaviors | Frequent (79-30%)"
Orphanet lists compulsive behaviors as frequent.
PMID:23365103 SUPPORT Human Clinical
"Obsessive-compulsive disorder was eight times more likely (P < 0.001) in mutation positive cases, compulsivity being the predominant feature (P < 0.001)."
This human cohort supports compulsivity/OCD as part of SGCE-related disease.
Anxiety FREQUENT Anxiety (HP:0000739)
Show evidence (2 references)
ORPHA:36899 SUPPORT Other
"HP:0000739 | Anxiety | Frequent (79-30%)"
Orphanet lists anxiety as frequent.
PMID:23365103 SUPPORT Human Clinical
"Generalized anxiety disorder (P = 0.003) and alcohol dependence (P = 0.02) were five times more likely in mutation positive cases than tremor controls."
This human cohort supports increased generalized anxiety disorder in SGCE mutation-positive cases.
Depression FREQUENT Depression (HP:0000716)
Show evidence (1 reference)
ORPHA:36899 SUPPORT Other
"HP:0000716 | Depression | Frequent (79-30%)"
Orphanet lists depression as frequent.
Other 7
Limb myoclonus VERY_FREQUENT Limb myoclonus (HP:0045084)
Show evidence (1 reference)
ORPHA:36899 SUPPORT Other
"HP:0045084 | Limb myoclonus | Very frequent (99-80%)"
Orphanet lists limb myoclonus as very frequent.
Spinal myoclonus VERY_FREQUENT Spinal myoclonus (HP:0010531)
Show evidence (1 reference)
ORPHA:36899 SUPPORT Other
"HP:0010531 | Spinal myoclonus | Very frequent (99-80%)"
Orphanet lists spinal myoclonus as very frequent.
Cervical dystonia FREQUENT Torticollis (HP:0000473)
Show evidence (2 references)
ORPHA:36899 SUPPORT Other
"HP:0000473 | Torticollis | Frequent (79-30%)"
Orphanet lists torticollis as frequent.
PMID:20301587 SUPPORT Human Clinical
"Approximately 50% of affected individuals have additional focal or segmental dystonia, presenting as cervical dystonia and/or writer's cramp."
GeneReviews identifies cervical dystonia as a common focal dystonia presentation.
Writer's cramp FREQUENT Writer's cramp (HP:0002356)
Show evidence (1 reference)
ORPHA:36899 SUPPORT Other
"HP:0002356 | Writer's cramp | Frequent (79-30%)"
Orphanet lists writer's cramp as frequent.
Panic attack FREQUENT Panic attack (HP:0025269)
Show evidence (1 reference)
ORPHA:36899 SUPPORT Other
"HP:0025269 | Panic attack | Frequent (79-30%)"
Orphanet lists panic attack as frequent.
Personality disorder FREQUENT Personality disorder (HP:0012075)
Show evidence (1 reference)
ORPHA:36899 SUPPORT Other
"HP:0012075 | Personality disorder | Frequent (79-30%)"
Orphanet lists personality disorder as frequent.
Addictive alcohol use Addictive alcohol use (HP:0030955)
Show evidence (2 references)
PMID:23365103 SUPPORT Human Clinical
"Generalized anxiety disorder (P = 0.003) and alcohol dependence (P = 0.02) were five times more likely in mutation positive cases than tremor controls."
This SGCE mutation-positive cohort supports alcohol dependence as part of the psychiatric phenotype.
PMID:31449710 SUPPORT Other
"Psychiatric symptomatology, namely, alcohol dependence and phobic and obsessive-compulsive disorder, is also part of the clinical picture."
This review identifies alcohol dependence as part of the clinical picture.
🧬

Genetic Associations

2
SGCE (Causative)
Show evidence (2 references)
ORPHA:36899 SUPPORT Other
"SGCE | sarcoglycan epsilon | hgnc:10808 | Disease-causing germline mutation(s) in"
Orphanet lists SGCE as disease-causing.
PMID:11528394 SUPPORT Human Clinical
"SGCE is expressed in all brain regions examined. Pedigree analysis shows a marked difference in penetrance depending on the parental origin of the disease allele."
This supports brain expression and imprinting-dependent penetrance of SGCE.
KCTD17 (Causative)
Show evidence (1 reference)
ORPHA:36899 SUPPORT Other
"KCTD17 | potassium channel tetramerization domain containing 17 | hgnc:25705 | Disease-causing germline mutation(s) in"
Orphanet lists KCTD17 as disease-causing.
💊

Treatments

6
Zonisamide
Action: Pharmacotherapy NCIT:C15986
Agent: zonisamide ↗
Zonisamide has randomized controlled trial evidence for improving myoclonus, myoclonus-related disability, and dystonia in myoclonus-dystonia syndrome.
Target Phenotypes: Myoclonus ↗ Dystonia ↗
Show evidence (2 references)
PMID:27053715 SUPPORT Human Clinical
"CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that zonisamide improves myoclonus and related disability in patients with myoclonus-dystonia."
This randomized crossover trial supports zonisamide as pharmacotherapy for myoclonus and related disability.
PMID:27053715 SUPPORT Human Clinical
"Zonisamide also significantly improved dystonia (BFM movement) compared to placebo"
The same randomized crossover trial supports a dystonia treatment effect.
Deep brain stimulation
Action: deep brain stimulation MAXO:0000943
Pallidal deep brain stimulation is a refractory treatment option for medically refractory myoclonus-dystonia, with long-term evidence favoring GPi stimulation for sustained motor and disability improvement.
Target Phenotypes: Myoclonus ↗ Dystonia ↗
Show evidence (1 reference)
PMID:33452690 SUPPORT Human Clinical
"We present a cohort of MD patients with very long follow-up of pallidal and/or thalamic DBS that supports the GPi as the favourable stimulation target in MD with safe and sustaining effects on motor symptoms (myoclonus>dystonia) and disability."
Long-term cohort data support DBS, especially GPi stimulation, for refractory motor symptoms.
Botulinum toxin injection
Action: botulinum toxin type A therapy MAXO:0009016
Botulinum toxin injection is a focal treatment option for cervical dystonia in myoclonus-dystonia syndrome.
Target Phenotypes: Cervical dystonia ↗
Show evidence (1 reference)
PMID:20301587 SUPPORT Human Clinical
"Botulinum toxin injection may be especially helpful for cervical dystonia."
GeneReviews supports botulinum toxin injection for the cervical dystonia component.
Clonazepam and benzodiazepine pharmacotherapy
Action: Pharmacotherapy NCIT:C15986
Agent: clonazepam ↗
Benzodiazepines, particularly clonazepam, may improve myoclonus symptoms in myoclonus-dystonia syndrome.
Target Phenotypes: Myoclonus ↗
Show evidence (1 reference)
PMID:20301587 SUPPORT Human Clinical
"Benzodiazepines (particularly clonazepam) and anti-seizure drugs used to treat myoclonus (especially valproate and levitiracetam) also improve myoclonus in individuals with myoclonus-dystonia."
GeneReviews supports clonazepam-containing benzodiazepine pharmacotherapy for myoclonus.
Anticholinergic medication
Action: Pharmacotherapy NCIT:C15986
Agent: Anticholinergic Agent ↗
Anticholinergic pharmacotherapy may improve dystonia in myoclonus-dystonia syndrome.
Target Phenotypes: Dystonia ↗
Show evidence (1 reference)
PMID:20301587 SUPPORT Human Clinical
"Anticholinergic medication may improve dystonia."
GeneReviews supports anticholinergic medication for dystonia.
Genetic counseling
Action: genetic counseling MAXO:0000079
Counseling addresses autosomal dominant transmission, imprinting-dependent penetrance, testing of relatives, and reproductive options once a familial SGCE variant is known.
Show evidence (1 reference)
PMID:20301587 SUPPORT Human Clinical
"Each child of an individual with SGCE-M-D has a 50% chance of inheriting the pathogenic variant."
GeneReviews supports recurrence-risk counseling for families with SGCE-related disease.
{ }

Source YAML

click to show 
name: Myoclonus-Dystonia Syndrome
creation_date: "2026-05-07T21:42:16Z"
updated_date: "2026-05-07T21:42:16Z"
category: Genetic
description: >-
  Myoclonus-dystonia syndrome is a rare, usually childhood-onset movement
  disorder characterized by brief myoclonic jerks with dystonia, prominent upper
  body involvement, alcohol responsiveness, and frequent psychiatric features.
  Pathogenic variants in SGCE, and less commonly KCTD17, disrupt movement-circuit
  function; SGCE-related disease shows autosomal dominant inheritance with
  maternal imprinting and reduced penetrance after maternal transmission.
synonyms:
- Alcohol-responsive dystonia
- Hereditary essential myoclonus
- Myoclonic dystonia
- SGCE myoclonus-dystonia
disease_term:
  preferred_term: myoclonus-dystonia syndrome
  term:
    id: MONDO:0000903
    label: myoclonus-dystonia syndrome
parents:
- dystonic disorder
- movement disorder
- autosomal dominant disease
prevalence:
- population: Europe
  percentage: 1-9 / 1,000,000
  notes: >-
    Orphanet reports a European point-prevalence band of 1-9 per 1,000,000.
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "| 1-9 / 1 000 000 | Europe | Point prevalence | ORPHANET |"
    explanation: Orphanet provides the prevalence class for myoclonus-dystonia syndrome.
inheritance:
- name: Autosomal dominant inheritance with maternal imprinting
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    SGCE-related myoclonus-dystonia is autosomal dominant, but penetrance depends
    on parental origin because maternally inherited SGCE alleles are usually
    silenced.
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "- Autosomal dominant"
    explanation: Orphanet lists autosomal dominant inheritance.
  - reference: PMID:20301587
    reference_title: SGCE Myoclonus-Dystonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SGCE-M-D is inherited in an autosomal dominant manner with penetrance
      determined by the parental origin of the altered SGCE allele: an SGCE
      pathogenic variant on the paternally derived (expressed) SGCE allele
      generally results in disease; a pathogenic variant on the maternally
      derived (silenced) SGCE allele typically does not result in disease.
    explanation: GeneReviews describes autosomal dominant inheritance with imprinting-dependent penetrance.
has_subtypes:
- name: SGCE-related myoclonus-dystonia
  display_name: Myoclonic dystonia 11
  subtype_term:
    preferred_term: myoclonic dystonia 11
    term:
      id: MONDO:0008044
      label: myoclonic dystonia 11
  description: >-
    SGCE-related myoclonus-dystonia is the major genetically defined form and is
    caused by pathogenic variants in SGCE.
  evidence:
  - reference: PMID:11528394
    reference_title: Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Using a positional cloning approach, we have identified five different
      heterozygous loss-of-function mutations in the gene for
      epsilon-sarcoglycan (SGCE), which we mapped to a refined critical region
      of about 3.2 Mb.
    explanation: This positional-cloning study establishes SGCE-related myoclonus-dystonia.
pathophysiology:
- name: Epsilon-sarcoglycan trafficking and membrane loss
  description: >-
    SGCE pathogenic variants reduce functional epsilon-sarcoglycan at the plasma
    membrane through intracellular retention, polyubiquitination, and proteasomal
    degradation of mutant protein.
  genes:
  - preferred_term: SGCE
    term:
      id: hgnc:10808
      label: SGCE
  biological_processes:
  - preferred_term: protein localization to plasma membrane
    term:
      id: GO:0072659
      label: protein localization to plasma membrane
    modifier: DECREASED
  - preferred_term: protein ubiquitination
    term:
      id: GO:0016567
      label: protein ubiquitination
    modifier: INCREASED
  downstream:
  - target: Altered cerebello-thalamic pathway function
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:17200151
    reference_title: "SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In contrast to the wild-type protein, disease-associated
      epsilon-sarcoglycan missense mutations (H36P, H36R and L172R) produce
      proteins that are undetectable at the cell surface and are retained
      intracellularly.
    explanation: Cultured-cell data directly support impaired plasma-membrane trafficking of mutant epsilon-sarcoglycan.
  - reference: PMID:17200151
    reference_title: "SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These mutant proteins become polyubiquitinated and are rapidly degraded by
      the proteasome.
    explanation: The same study supports ubiquitin-proteasome processing of mutant epsilon-sarcoglycan.
- name: GABAergic/Purkinje cell dysfunction
  description: >-
    Myoclonus-dystonia motor-network dysfunction may involve a GABAergic deficit
    reflecting Purkinje-cell dysfunction.
  cell_types:
  - preferred_term: Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
  biological_processes:
  - preferred_term: synaptic transmission, GABAergic
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
    modifier: DECREASED
  downstream:
  - target: Altered cerebello-thalamic pathway function
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:29952836
    reference_title: "Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Accumulating evidence suggests that an alteration in cerebello-thalamic
      pathway function may play a prominent role and that this is possibly
      related to a GABAergic deficit reflecting Purkinje cell dysfunction.
    explanation: This review supports GABAergic/Purkinje-cell dysfunction as an intermediate mechanism.
- name: Impaired striatal plasticity
  description: >-
    Impaired striatal plasticity is implicated as a basal-ganglia circuit
    mechanism contributing to the myoclonus-dystonia motor phenotype.
  biological_processes:
  - preferred_term: regulation of synaptic plasticity
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
    modifier: DECREASED
  downstream:
  - target: Myoclonus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Limb myoclonus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Spinal myoclonus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Dystonia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:29952836
    reference_title: "Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Impaired striatal plasticity and disturbed serotonin homeostasis may also
      be implicated.
    explanation: This review supports impaired striatal plasticity as a separate motor-circuit mechanism.
- name: Disturbed serotonin homeostasis
  description: >-
    Disturbed serotonin homeostasis is implicated as another neurotransmitter
    mechanism in the myoclonus-dystonia motor circuit.
  downstream:
  - target: Myoclonus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Dystonia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:29952836
    reference_title: "Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Impaired striatal plasticity and disturbed serotonin homeostasis may also
      be implicated.
    explanation: This review supports disturbed serotonin homeostasis as a distinct implicated mechanism.
- name: Calcium homeostasis disturbance
  description: >-
    Epsilon-sarcoglycan dysfunction may alter calcium homeostasis and
    dopaminergic membrane stabilization, contributing to abnormal
    cerebello-thalamo-pallido-cortical network development and function.
  biological_processes:
  - preferred_term: calcium ion homeostasis
    term:
      id: GO:0055074
      label: calcium ion homeostasis
    modifier: ABNORMAL
  downstream:
  - target: Altered cerebello-thalamic pathway function
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:31449710
    reference_title: "Twenty years on: Myoclonus-dystonia and ε-sarcoglycan - neurodevelopment, channel, and signaling dysfunction."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Finally, we critically discuss the normal and pathological function of the
      epsilon-sarcoglycan gene and its product, suggesting a role in the
      stabilization of the dopaminergic membrane via regulation of calcium
      homeostasis and in the neurodevelopmental process involving the
      cerebello-thalamo-pallido-cortical network.
    explanation: This mechanistic review supports calcium-homeostasis disturbance as a distinct epsilon-sarcoglycan mechanism.
- name: Altered cerebello-thalamic pathway function
  description: >-
    Altered cerebello-thalamic pathway function is the central motor-network
    event linking upstream SGCE mechanisms to myoclonus and dystonia.
  downstream:
  - target: Myoclonus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Limb myoclonus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Spinal myoclonus
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Dystonia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Cervical dystonia
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Writer's cramp
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:29952836
    reference_title: "Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Accumulating evidence suggests that an alteration in cerebello-thalamic
      pathway function may play a prominent role and that this is possibly
      related to a GABAergic deficit reflecting Purkinje cell dysfunction.
    explanation: This review supports altered cerebello-thalamic pathway function as a central mechanism.
  - reference: PMID:31449710
    reference_title: "Twenty years on: Myoclonus-dystonia and ε-sarcoglycan - neurodevelopment, channel, and signaling dysfunction."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Finally, we critically discuss the normal and pathological function of the
      epsilon-sarcoglycan gene and its product, suggesting a role in the
      stabilization of the dopaminergic membrane via regulation of calcium
      homeostasis and in the neurodevelopmental process involving the
      cerebello-thalamo-pallido-cortical network.
    explanation: This mechanistic review supports cerebello-thalamo-pallido-cortical network involvement.
- name: SGCE-associated psychiatric vulnerability
  description: >-
    SGCE pathogenic variants have pleiotropic neuropsychiatric effects that
    increase compulsivity, anxiety, alcohol dependence, and other psychiatric
    symptoms in addition to the motor phenotype.
  genes:
  - preferred_term: SGCE
    term:
      id: hgnc:10808
      label: SGCE
  downstream:
  - target: Compulsive behaviors
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Anxiety
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Depression
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Panic attack
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:23365103
    reference_title: "SGCE mutations cause psychiatric disorders: clinical and genetic characterization."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SGCE mutations are associated with a specific psychiatric phenotype
      consisting of compulsivity, anxiety and alcoholism in addition to the
      characteristic motor phenotype.
    explanation: This SGCE mutation-positive cohort supports psychiatric vulnerability as part of the syndrome.
phenotypes:
- category: Neurologic
  name: Myoclonus
  frequency: VERY_FREQUENT
  description: >-
    Rapid brief myoclonic jerks are a defining and often predominant motor
    manifestation of myoclonus-dystonia syndrome.
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001336 | Myoclonus | Very frequent (99-80%)"
    explanation: Orphanet lists myoclonus as very frequent.
  - reference: PMID:20301587
    reference_title: SGCE Myoclonus-Dystonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The myoclonic jerks typical of SGCE-M-D most often affect the neck, trunk,
      and upper limbs with less common involvement of the legs.
    explanation: GeneReviews describes the distribution of typical SGCE-related myoclonic jerks.
- category: Neurologic
  name: Limb myoclonus
  frequency: VERY_FREQUENT
  description: >-
    Upper-limb and other limb myoclonic jerks are characteristic, supporting the
    prominent upper-body phenotype.
  phenotype_term:
    preferred_term: Limb myoclonus
    term:
      id: HP:0045084
      label: Limb myoclonus
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0045084 | Limb myoclonus | Very frequent (99-80%)"
    explanation: Orphanet lists limb myoclonus as very frequent.
- category: Neurologic
  name: Spinal myoclonus
  frequency: VERY_FREQUENT
  description: >-
    Orphanet lists spinal myoclonus as a very frequent myoclonus subtype in the
    syndrome phenotype profile.
  phenotype_term:
    preferred_term: Spinal myoclonus
    term:
      id: HP:0010531
      label: Spinal myoclonus
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0010531 | Spinal myoclonus | Very frequent (99-80%)"
    explanation: Orphanet lists spinal myoclonus as very frequent.
- category: Neurologic
  name: Dystonia
  frequency: VERY_FREQUENT
  description: >-
    Dystonia accompanies myoclonus and may be focal or segmental.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001332 | Dystonia | Very frequent (99-80%)"
    explanation: Orphanet lists dystonia as very frequent.
  - reference: PMID:20301587
    reference_title: SGCE Myoclonus-Dystonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Approximately 50% of affected individuals have additional focal or
      segmental dystonia, presenting as cervical dystonia and/or writer's cramp.
    explanation: GeneReviews supports focal or segmental dystonia as part of SGCE-related disease.
- category: Neurologic
  name: Cervical dystonia
  frequency: FREQUENT
  description: >-
    Cervical dystonia or torticollis is a common focal dystonia manifestation.
  phenotype_term:
    preferred_term: Cervical dystonia
    term:
      id: HP:0000473
      label: Torticollis
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000473 | Torticollis | Frequent (79-30%)"
    explanation: Orphanet lists torticollis as frequent.
  - reference: PMID:20301587
    reference_title: SGCE Myoclonus-Dystonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Approximately 50% of affected individuals have additional focal or
      segmental dystonia, presenting as cervical dystonia and/or writer's cramp.
    explanation: GeneReviews identifies cervical dystonia as a common focal dystonia presentation.
- category: Neurologic
  name: Writer's cramp
  frequency: FREQUENT
  description: >-
    Writer's cramp is a frequent focal hand dystonia presentation.
  phenotype_term:
    preferred_term: Writer's cramp
    term:
      id: HP:0002356
      label: Writer's cramp
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002356 | Writer's cramp | Frequent (79-30%)"
    explanation: Orphanet lists writer's cramp as frequent.
- category: Psychiatric
  name: Compulsive behaviors
  frequency: FREQUENT
  description: >-
    Obsessive-compulsive symptoms and compulsivity are frequent non-motor
    manifestations.
  phenotype_term:
    preferred_term: Compulsive behaviors
    term:
      id: HP:0000722
      label: Compulsive behaviors
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000722 | Compulsive behaviors | Frequent (79-30%)"
    explanation: Orphanet lists compulsive behaviors as frequent.
  - reference: PMID:23365103
    reference_title: "SGCE mutations cause psychiatric disorders: clinical and genetic characterization."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Obsessive-compulsive disorder was eight times more likely (P < 0.001) in
      mutation positive cases, compulsivity being the predominant feature (P <
      0.001).
    explanation: This human cohort supports compulsivity/OCD as part of SGCE-related disease.
- category: Psychiatric
  name: Anxiety
  frequency: FREQUENT
  description: >-
    Anxiety disorders are common non-motor manifestations in SGCE-related
    myoclonus-dystonia.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000739 | Anxiety | Frequent (79-30%)"
    explanation: Orphanet lists anxiety as frequent.
  - reference: PMID:23365103
    reference_title: "SGCE mutations cause psychiatric disorders: clinical and genetic characterization."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Generalized anxiety disorder (P = 0.003) and alcohol dependence (P = 0.02)
      were five times more likely in mutation positive cases than tremor
      controls.
    explanation: This human cohort supports increased generalized anxiety disorder in SGCE mutation-positive cases.
- category: Psychiatric
  name: Depression
  frequency: FREQUENT
  description: >-
    Depression is included among frequent psychiatric manifestations in the
    Orphanet phenotype profile.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000716 | Depression | Frequent (79-30%)"
    explanation: Orphanet lists depression as frequent.
- category: Psychiatric
  name: Panic attack
  frequency: FREQUENT
  description: >-
    Panic attacks are included among frequent psychiatric manifestations in the
    Orphanet phenotype profile.
  phenotype_term:
    preferred_term: Panic attack
    term:
      id: HP:0025269
      label: Panic attack
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0025269 | Panic attack | Frequent (79-30%)"
    explanation: Orphanet lists panic attack as frequent.
- category: Psychiatric
  name: Personality disorder
  frequency: FREQUENT
  description: >-
    Personality disorder is included among frequent psychiatric manifestations
    in the Orphanet phenotype profile.
  phenotype_term:
    preferred_term: Personality disorder
    term:
      id: HP:0012075
      label: Personality disorder
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0012075 | Personality disorder | Frequent (79-30%)"
    explanation: Orphanet lists personality disorder as frequent.
- category: Psychiatric
  name: Addictive alcohol use
  description: >-
    Alcohol dependence and alcohol abuse are distinctive non-motor features in
    SGCE-related myoclonus-dystonia.
  phenotype_term:
    preferred_term: Addictive alcohol use
    term:
      id: HP:0030955
      label: Addictive alcohol use
  evidence:
  - reference: PMID:23365103
    reference_title: "SGCE mutations cause psychiatric disorders: clinical and genetic characterization."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Generalized anxiety disorder (P = 0.003) and alcohol dependence (P = 0.02)
      were five times more likely in mutation positive cases than tremor
      controls.
    explanation: This SGCE mutation-positive cohort supports alcohol dependence as part of the psychiatric phenotype.
  - reference: PMID:31449710
    reference_title: "Twenty years on: Myoclonus-dystonia and ε-sarcoglycan - neurodevelopment, channel, and signaling dysfunction."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Psychiatric symptomatology, namely, alcohol dependence and phobic and
      obsessive-compulsive disorder, is also part of the clinical picture.
    explanation: This review identifies alcohol dependence as part of the clinical picture.
genetic:
- name: SGCE
  association: Causative
  presence: Positive
  gene_term:
    preferred_term: SGCE
    term:
      id: hgnc:10808
      label: SGCE
  notes: >-
    SGCE is the major causative gene and shows parental-origin-dependent
    penetrance because maternally transmitted alleles are usually silenced.
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SGCE | sarcoglycan epsilon | hgnc:10808 | Disease-causing germline mutation(s) in"
    explanation: Orphanet lists SGCE as disease-causing.
  - reference: PMID:11528394
    reference_title: Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SGCE is expressed in all brain regions examined. Pedigree analysis shows a
      marked difference in penetrance depending on the parental origin of the
      disease allele.
    explanation: This supports brain expression and imprinting-dependent penetrance of SGCE.
- name: KCTD17
  association: Causative
  presence: Positive
  gene_term:
    preferred_term: KCTD17
    term:
      id: hgnc:25705
      label: KCTD17
  notes: >-
    KCTD17 is a rarer disease-causing gene in the broader Orphanet
    myoclonus-dystonia syndrome record.
  evidence:
  - reference: ORPHA:36899
    reference_title: Myoclonus-dystonia syndrome
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "KCTD17 | potassium channel tetramerization domain containing 17 | hgnc:25705 | Disease-causing germline mutation(s) in"
    explanation: Orphanet lists KCTD17 as disease-causing.
diagnosis:
- name: SGCE and movement-disorder gene testing
  description: >-
    Molecular testing for SGCE pathogenic variants, with copy-number analysis
    and consideration of related dystonia genes when SGCE is negative, supports
    diagnosis in patients with characteristic early-onset upper-body
    myoclonus-dystonia.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  results: SGCE or other myoclonus-dystonia-associated pathogenic variant.
  evidence:
  - reference: PMID:20301587
    reference_title: SGCE Myoclonus-Dystonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of SGCE-M-D is established in a proband with characteristic
      clinical features by identification of a heterozygous pathogenic variant
      in SGCE.
    explanation: GeneReviews defines SGCE molecular testing as diagnostic when clinical features fit.
  - reference: PMID:25209853
    reference_title: "SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our data confirms that SGCE mutations are most commonly identified in MDS
      patients with (1) age at onset ≤10 years and (2) predominant upper body
      involvement of a pure myoclonus-dystonia.
    explanation: This cohort identifies clinical predictors that guide SGCE testing.
treatments:
- name: Zonisamide
  description: >-
    Zonisamide has randomized controlled trial evidence for improving myoclonus,
    myoclonus-related disability, and dystonia in myoclonus-dystonia syndrome.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: zonisamide
      term:
        id: CHEBI:10127
        label: zonisamide
  target_phenotypes:
  - preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  - preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:27053715
    reference_title: "A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that
      zonisamide improves myoclonus and related disability in patients with
      myoclonus-dystonia.
    explanation: This randomized crossover trial supports zonisamide as pharmacotherapy for myoclonus and related disability.
  - reference: PMID:27053715
    reference_title: "A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Zonisamide also significantly improved dystonia (BFM movement) compared
      to placebo
    explanation: The same randomized crossover trial supports a dystonia treatment effect.
- name: Deep brain stimulation
  description: >-
    Pallidal deep brain stimulation is a refractory treatment option for
    medically refractory myoclonus-dystonia, with long-term evidence favoring
    GPi stimulation for sustained motor and disability improvement.
  treatment_term:
    preferred_term: deep brain stimulation
    term:
      id: MAXO:0000943
      label: deep brain stimulation
  target_phenotypes:
  - preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  - preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:33452690
    reference_title: Long-term effects of pallidal and thalamic deep brain stimulation in myoclonus dystonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present a cohort of MD patients with very long follow-up of pallidal
      and/or thalamic DBS that supports the GPi as the favourable stimulation
      target in MD with safe and sustaining effects on motor symptoms
      (myoclonus>dystonia) and disability.
    explanation: Long-term cohort data support DBS, especially GPi stimulation, for refractory motor symptoms.
- name: Botulinum toxin injection
  description: >-
    Botulinum toxin injection is a focal treatment option for cervical dystonia
    in myoclonus-dystonia syndrome.
  treatment_term:
    preferred_term: botulinum toxin type A therapy
    term:
      id: MAXO:0009016
      label: botulinum toxin type A therapy
  target_phenotypes:
  - preferred_term: Cervical dystonia
    term:
      id: HP:0000473
      label: Torticollis
  evidence:
  - reference: PMID:20301587
    reference_title: SGCE Myoclonus-Dystonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Botulinum toxin injection may be especially helpful for cervical dystonia.
    explanation: GeneReviews supports botulinum toxin injection for the cervical dystonia component.
- name: Clonazepam and benzodiazepine pharmacotherapy
  description: >-
    Benzodiazepines, particularly clonazepam, may improve myoclonus symptoms in
    myoclonus-dystonia syndrome.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: clonazepam
      term:
        id: CHEBI:3756
        label: clonazepam
  target_phenotypes:
  - preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: PMID:20301587
    reference_title: SGCE Myoclonus-Dystonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Benzodiazepines (particularly clonazepam) and anti-seizure drugs used to
      treat myoclonus (especially valproate and levitiracetam) also improve
      myoclonus in individuals with myoclonus-dystonia.
    explanation: GeneReviews supports clonazepam-containing benzodiazepine pharmacotherapy for myoclonus.
- name: Anticholinergic medication
  description: >-
    Anticholinergic pharmacotherapy may improve dystonia in
    myoclonus-dystonia syndrome.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Anticholinergic Agent
      term:
        id: NCIT:C66880
        label: Anticholinergic Agent
  target_phenotypes:
  - preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:20301587
    reference_title: SGCE Myoclonus-Dystonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Anticholinergic medication may improve dystonia.
    explanation: GeneReviews supports anticholinergic medication for dystonia.
- name: Genetic counseling
  description: >-
    Counseling addresses autosomal dominant transmission, imprinting-dependent
    penetrance, testing of relatives, and reproductive options once a familial
    SGCE variant is known.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:20301587
    reference_title: SGCE Myoclonus-Dystonia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Each child of an individual with SGCE-M-D has a 50% chance of inheriting
      the pathogenic variant.
    explanation: GeneReviews supports recurrence-risk counseling for families with SGCE-related disease.
clinical_trials: []
datasets: []
references:
- reference: ORPHA:36899
  title: Myoclonus-dystonia syndrome
  found_in:
  - Myoclonus_Dystonia_Syndrome-deep-research-fallback.md
  findings:
  - statement: >-
      Orphanet defines myoclonus-dystonia syndrome by dystonia with
      lightning-like myoclonic jerks and provides inheritance, prevalence, gene,
      phenotype, and MONDO cross-reference rows.
    supporting_text: >-
      Myoclonus-dystonia syndrome (MDS) is a rare movement disorder
      characterized by mild to moderate dystonia along with 'lightning-like'
      myoclonic jerks.
- reference: PMID:20301587
  title: SGCE Myoclonus-Dystonia.
  found_in:
  - Myoclonus_Dystonia_Syndrome-deep-research-fallback.md
  findings:
  - statement: >-
      GeneReviews supports the SGCE-M-D clinical syndrome, diagnostic testing,
      treatment options, alcohol responsiveness, and maternal-imprinting
      inheritance pattern.
    supporting_text: >-
      SGCE myoclonus-dystonia (SGCE-M-D) is a movement disorder characterized
      by a combination of rapid, brief muscle contractions (myoclonus) and/or
      sustained twisting and repetitive movements that result in abnormal
      postures (dystonia).
- reference: PMID:11528394
  title: Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome.
  found_in:
  - Myoclonus_Dystonia_Syndrome-deep-research-fallback.md
  findings:
  - statement: >-
      Positional cloning identified heterozygous SGCE loss-of-function variants
      as a cause of myoclonus-dystonia syndrome.
    supporting_text: >-
      Using a positional cloning approach, we have identified five different
      heterozygous loss-of-function mutations in the gene for
      epsilon-sarcoglycan (SGCE), which we mapped to a refined critical region
      of about 3.2 Mb.
- reference: PMID:17200151
  title: "SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA."
  found_in:
  - Myoclonus_Dystonia_Syndrome-deep-research-fallback.md
  findings:
  - statement: >-
      SGCE missense variants impair epsilon-sarcoglycan cell-surface
      trafficking and promote polyubiquitination and proteasomal degradation.
    supporting_text: >-
      These data demonstrate that some MDS-associated mutations in SGCE impair
      trafficking of the mutant protein to the plasma membrane and suggest a
      role for torsinA and the ubiquitin proteasome system in the recognition
      and processing of misfolded epsilon-sarcoglycan.
- reference: PMID:25209853
  title: "SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype."
  found_in:
  - Myoclonus_Dystonia_Syndrome-deep-research-fallback.md
  findings:
  - statement: >-
      SGCE-positive cases are enriched for early-onset predominant upper-body
      pure myoclonus-dystonia.
    supporting_text: >-
      Our data confirms that SGCE mutations are most commonly identified in MDS
      patients with (1) age at onset ≤10 years and (2) predominant upper body
      involvement of a pure myoclonus-dystonia.
- reference: PMID:23365103
  title: "SGCE mutations cause psychiatric disorders: clinical and genetic characterization."
  found_in:
  - Myoclonus_Dystonia_Syndrome-deep-research-fallback.md
  findings:
  - statement: >-
      SGCE mutation-positive individuals have a characteristic psychiatric
      phenotype including compulsivity, anxiety, and alcoholism.
    supporting_text: >-
      SGCE mutations are associated with a specific psychiatric phenotype
      consisting of compulsivity, anxiety and alcoholism in addition to the
      characteristic motor phenotype.
- reference: PMID:27053715
  title: "A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia."
  found_in:
  - Myoclonus_Dystonia_Syndrome-deep-research-fallback.md
  findings:
  - statement: >-
      A randomized crossover trial provides class I evidence that zonisamide
      improves myoclonus and related disability.
    supporting_text: >-
      CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that
      zonisamide improves myoclonus and related disability in patients with
      myoclonus-dystonia.
- reference: PMID:33452690
  title: Long-term effects of pallidal and thalamic deep brain stimulation in myoclonus dystonia.
  found_in:
  - Myoclonus_Dystonia_Syndrome-deep-research-fallback.md
  findings:
  - statement: >-
      Long-term DBS evidence supports GPi as a favorable stimulation target for
      refractory myoclonus-dystonia.
    supporting_text: >-
      We present a cohort of MD patients with very long follow-up of pallidal
      and/or thalamic DBS that supports the GPi as the favourable stimulation
      target in MD with safe and sustaining effects on motor symptoms
      (myoclonus>dystonia) and disability.
- reference: PMID:29952836
  title: "Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment."
  found_in:
  - Myoclonus_Dystonia_Syndrome-deep-research-fallback.md
  findings:
  - statement: >-
      Review evidence supports cerebello-thalamic pathway dysfunction,
      GABAergic/Purkinje-cell dysfunction, striatal plasticity, serotonin
      homeostasis, zonisamide, and pallidal stimulation.
    supporting_text: >-
      Accumulating evidence suggests that an alteration in cerebello-thalamic
      pathway function may play a prominent role and that this is possibly
      related to a GABAergic deficit reflecting Purkinje cell dysfunction.
- reference: PMID:31449710
  title: "Twenty years on: Myoclonus-dystonia and ε-sarcoglycan - neurodevelopment, channel, and signaling dysfunction."
  found_in:
  - Myoclonus_Dystonia_Syndrome-deep-research-fallback.md
  findings:
  - statement: >-
      Review evidence links epsilon-sarcoglycan dysfunction to dopaminergic
      membrane stabilization, calcium homeostasis, neurodevelopment, and the
      cerebello-thalamo-pallido-cortical network.
    supporting_text: >-
      Finally, we critically discuss the normal and pathological function of the
      epsilon-sarcoglycan gene and its product, suggesting a role in the
      stabilization of the dopaminergic membrane via regulation of calcium
      homeostasis and in the neurodevelopmental process involving the
      cerebello-thalamo-pallido-cortical network.
review_notes: >-
  KCTD17 is included as an Orphanet-supported rare causative gene, but the YAML
  emphasizes SGCE-related myoclonus-dystonia because SGCE is the major
  genetically defined and best-evidenced form with dedicated clinical,
  mechanistic, diagnostic, and treatment literature.
📚

References & Deep Research

References

10
ORPHA:36899
Myoclonus-dystonia syndrome
1 finding
Orphanet defines myoclonus-dystonia syndrome by dystonia with lightning-like myoclonic jerks and provides inheritance, prevalence, gene, phenotype, and MONDO cross-reference rows.
"Myoclonus-dystonia syndrome (MDS) is a rare movement disorder characterized by mild to moderate dystonia along with 'lightning-like' myoclonic jerks."
PMID:20301587
SGCE Myoclonus-Dystonia.
1 finding
GeneReviews supports the SGCE-M-D clinical syndrome, diagnostic testing, treatment options, alcohol responsiveness, and maternal-imprinting inheritance pattern.
"SGCE myoclonus-dystonia (SGCE-M-D) is a movement disorder characterized by a combination of rapid, brief muscle contractions (myoclonus) and/or sustained twisting and repetitive movements that result in abnormal postures (dystonia)."
PMID:11528394
Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome.
1 finding
Positional cloning identified heterozygous SGCE loss-of-function variants as a cause of myoclonus-dystonia syndrome.
"Using a positional cloning approach, we have identified five different heterozygous loss-of-function mutations in the gene for epsilon-sarcoglycan (SGCE), which we mapped to a refined critical region of about 3.2 Mb."
PMID:17200151
SGCE missense mutations that cause myoclonus-dystonia syndrome impair epsilon-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA.
1 finding
SGCE missense variants impair epsilon-sarcoglycan cell-surface trafficking and promote polyubiquitination and proteasomal degradation.
"These data demonstrate that some MDS-associated mutations in SGCE impair trafficking of the mutant protein to the plasma membrane and suggest a role for torsinA and the ubiquitin proteasome system in the recognition and processing of misfolded epsilon-sarcoglycan."
PMID:25209853
SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype.
1 finding
SGCE-positive cases are enriched for early-onset predominant upper-body pure myoclonus-dystonia.
"Our data confirms that SGCE mutations are most commonly identified in MDS patients with (1) age at onset ≤10 years and (2) predominant upper body involvement of a pure myoclonus-dystonia."
PMID:23365103
SGCE mutations cause psychiatric disorders: clinical and genetic characterization.
1 finding
SGCE mutation-positive individuals have a characteristic psychiatric phenotype including compulsivity, anxiety, and alcoholism.
"SGCE mutations are associated with a specific psychiatric phenotype consisting of compulsivity, anxiety and alcoholism in addition to the characteristic motor phenotype."
PMID:27053715
A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia.
1 finding
A randomized crossover trial provides class I evidence that zonisamide improves myoclonus and related disability.
"CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that zonisamide improves myoclonus and related disability in patients with myoclonus-dystonia."
PMID:33452690
Long-term effects of pallidal and thalamic deep brain stimulation in myoclonus dystonia.
1 finding
Long-term DBS evidence supports GPi as a favorable stimulation target for refractory myoclonus-dystonia.
"We present a cohort of MD patients with very long follow-up of pallidal and/or thalamic DBS that supports the GPi as the favourable stimulation target in MD with safe and sustaining effects on motor symptoms (myoclonus>dystonia) and disability."
PMID:29952836
Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment.
1 finding
Review evidence supports cerebello-thalamic pathway dysfunction, GABAergic/Purkinje-cell dysfunction, striatal plasticity, serotonin homeostasis, zonisamide, and pallidal stimulation.
"Accumulating evidence suggests that an alteration in cerebello-thalamic pathway function may play a prominent role and that this is possibly related to a GABAergic deficit reflecting Purkinje cell dysfunction."
PMID:31449710
Twenty years on: Myoclonus-dystonia and ε-sarcoglycan - neurodevelopment, channel, and signaling dysfunction.
1 finding
Review evidence links epsilon-sarcoglycan dysfunction to dopaminergic membrane stabilization, calcium homeostasis, neurodevelopment, and the cerebello-thalamo-pallido-cortical network.
"Finally, we critically discuss the normal and pathological function of the epsilon-sarcoglycan gene and its product, suggesting a role in the stabilization of the dopaminergic membrane via regulation of calcium homeostasis and in the neurodevelopmental process involving the..."

Deep Research

1
Myoclonus-Dystonia Syndrome Evidence-Backed Research Fallback ▸

Myoclonus-Dystonia Syndrome Evidence-Backed Research Fallback

Provider Attempts

Both bounded deep-research providers failed to return usable artifacts. Falcon timed out after 180 seconds, and the secondary OpenAI run also timed out after 180 seconds. No partial provider research file was left on disk, so the curation uses fetched Orphanet and PubMed cache evidence.

Evidence Synthesis

ORPHA:36899 defines myoclonus-dystonia syndrome as a rare movement disorder with mild-to-moderate dystonia and lightning-like myoclonic jerks. The structured record supplies the European point-prevalence band, autosomal dominant inheritance, disease-causing SGCE and KCTD17 gene rows, MONDO:0000903 exact mapping, and HPO phenotype frequencies for myoclonus, limb myoclonus, dystonia, torticollis, spinal myoclonus, writer's cramp, compulsive behaviors, anxiety, depression, panic attack, and personality disorder.

PMID:20301587 provides the clinical GeneReviews frame for SGCE myoclonus-dystonia: rapid myoclonus and dystonia, typical neck/trunk/upper-limb distribution, additional focal dystonia including cervical dystonia and writer's cramp, alcohol responsiveness, diagnosis by heterozygous SGCE pathogenic variant, treatment options including zonisamide, clonazepam-containing benzodiazepine pharmacotherapy, botulinum toxin injection, anticholinergic medication, deep brain stimulation, and autosomal dominant inheritance with parental-origin-dependent penetrance.

PMID:11528394 is the key SGCE discovery paper. It describes autosomal dominant, alcohol-sensitive myoclonic jerks with dystonia and psychiatric abnormalities, then reports heterozygous SGCE loss-of-function variants mapped by positional cloning. It also supports SGCE brain expression and maternal-imprinting penetrance differences.

PMID:17200151 supports the protein-processing mechanism. Disease-associated epsilon-sarcoglycan missense variants fail to reach the cell surface, are retained intracellularly, become polyubiquitinated, and are rapidly degraded by the proteasome. The YAML therefore models impaired plasma-membrane localization and increased ubiquitination as an upstream mechanism.

PMID:29952836 and PMID:31449710 provide review-level mechanistic synthesis for the downstream motor network. They implicate altered cerebello-thalamic pathway function, possible GABAergic/Purkinje-cell dysfunction, striatal plasticity, serotonin homeostasis, calcium homeostasis, dopaminergic-membrane stabilization, and the cerebello-thalamo-pallido-cortical network.

PMID:25209853 supports diagnostic phenotype predictors for SGCE-positive cases: age at onset no later than 10 years and predominant upper-body involvement of pure myoclonus-dystonia. PMID:23365103 supports the psychiatric component in SGCE mutation-positive individuals, especially compulsivity, anxiety, and alcoholism; PMID:31449710 independently lists alcohol dependence as part of the clinical picture.

PMID:27053715 provides class I randomized crossover trial evidence that zonisamide improves myoclonus and related disability. PMID:33452690 supports deep brain stimulation, especially GPi stimulation, as a long-term treatment option for medically refractory myoclonus-dystonia.

Scope Confirmation

The YAML emphasizes the SGCE-related form because it is the best-evidenced and major genetically defined subtype, but it retains KCTD17 as an Orphanet-listed disease-causing gene. Evidence blocks avoid the title-only KCTD17 DOI cache and use only exact snippets from cache-backed Orphanet and PubMed references.